203695 | bpV(phen) - CAS 42494-73-5 - Calbiochem

203695
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Specifications Table

      Empirical FormulaCAS #
      K[VO(O₂)₂C₁₂H₈N₂] 42494-73-5

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      203695-10MG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Plastic ampoule 10 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewA potent protein phosphotyrosine phosphatase inhibitor and insulin receptor kinase (IRK) activator. Excellent insulin mimetic at 15 µg/kg in vitro and in vivo for use. Inhibits the in situ dephosphorylation of autophosphorylated insulin receptors with over 1000-fold greater potency than sodium orthovanadate. Arrests proliferation of neuroblastoma NB 41 and glioma C6 cells at the G2/M transition of the cell cycle. Also reported to potently inhibit PTEN (IC50 = 38 nM).
          The water content varies from lot to lot and is supplied on the label along with the lot-specific molecular weight.
          Catalogue Number203695
          Brand Family Calbiochem®
          SynonymsPotassium Bisperoxo(1,10-phenanthroline)oxovanadate (V), PTEN Inhibitor I, PTP Inhibitor VIII
          References
          ReferencesSchmid, A.C., et al. 2004. FEBS Lett. 566, 35.
          Muzyamba, M.C., et al. 1999. J. Physiol. 517, 421.
          Drake, P.G., et al. 1996. Endocrinology 137, 4960.
          Bevan, A.P., et al. 1995. Am. J. Physiol. 268, E60.
          Bevan, A.P., et al. 1995. J. Biol. Chem. 270, 10784.
          Yale, J.F., et al. 1995. Diabetes 44, 1274.
          Posner, B.I., et al. 1994. J. Biol. Chem. 269, 4596.
          Product Information
          CAS number42494-73-5
          ATP CompetitiveN
          FormYellow solid
          Hill FormulaK[VO(O₂)₂C₁₂H₈N₂]
          Chemical formulaK[VO(O₂)₂C₁₂H₈N₂]
          ReversibleN
          Structure formula ImageStructure formula Image
          Applications
          ApplicationbpV(phen, CAS 42494-73-5, is an insulin mimetic and an inhibitor of protein phosphotyrosine phosphatase. More potent in dephosphorylating of autophosphorylated insulin receptor than orthovanadate.
          Biological Information
          Primary TargetPTEN
          Primary Target IC<sub>50</sub>38 nM
          Purity≥99% by ⁵¹V-NMR
          Physicochemical Information
          Cell permeableN
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Standard Handling
          Storage -20°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsUnstable in solution; reconstitute just prior to use.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          203695

          References

          Reference overview
          Schmid, A.C., et al. 2004. FEBS Lett. 566, 35.
          Muzyamba, M.C., et al. 1999. J. Physiol. 517, 421.
          Drake, P.G., et al. 1996. Endocrinology 137, 4960.
          Bevan, A.P., et al. 1995. Am. J. Physiol. 268, E60.
          Bevan, A.P., et al. 1995. J. Biol. Chem. 270, 10784.
          Yale, J.F., et al. 1995. Diabetes 44, 1274.
          Posner, B.I., et al. 1994. J. Biol. Chem. 269, 4596.

          Brochure

          Title
          Protein Phosphatases Technical Bulletin
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision15-May-2012 JSW
          SynonymsPotassium Bisperoxo(1,10-phenanthroline)oxovanadate (V), PTEN Inhibitor I, PTP Inhibitor VIII
          DescriptionA potent insulin receptor kinase (IRK) activator and protein phosphotyrosine phosphatase inhibitor. Excellent insulin mimetic for in vitro and in vivo use (15 µg/kg). Inhibits in situ dephosphorylation of autophosphorylated insulin receptors with greater than 1000-fold potency over sodium orthovanadate. Arrests proliferation of neuroblastoma NB 41 and glioma C6 cells at the G2/M transition of the cell cycle. Also reported to potently inhibit PTEN (IC50 = 38 nM). The water content varies from lot to lot and is supplied on the label along with the lot-specific molecular weight.
          FormYellow solid
          Intert gas (Yes/No) Packaged under inert gas
          CAS number42494-73-5
          Chemical formulaK[VO(O₂)₂C₁₂H₈N₂]
          Structure formulaStructure formula
          Purity≥99% by ⁵¹V-NMR
          SolubilityH₂O (5 mg/ml)
          Storage -20°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsUnstable in solution; reconstitute just prior to use.
          Toxicity Standard Handling
          ReferencesSchmid, A.C., et al. 2004. FEBS Lett. 566, 35.
          Muzyamba, M.C., et al. 1999. J. Physiol. 517, 421.
          Drake, P.G., et al. 1996. Endocrinology 137, 4960.
          Bevan, A.P., et al. 1995. Am. J. Physiol. 268, E60.
          Bevan, A.P., et al. 1995. J. Biol. Chem. 270, 10784.
          Yale, J.F., et al. 1995. Diabetes 44, 1274.
          Posner, B.I., et al. 1994. J. Biol. Chem. 269, 4596.